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ABSTRACT
Cyclin D1 (Ccnd1) is a proto-oncogen amplified in many different cancers and 
nuclear accumulation of Ccnd1 is a characteristic of tumor cells. Ccnd1 activates the 
transcription of a large set of genes involved in cell cycle progress and proliferation. 
However, Ccnd1 also targets cytoplasmic proteins involved in the regulation of cell 
migration and invasion. In this work, we have analyzed by immunohistochemistry 
the localization of Ccnd1 in endometrial, breast, prostate and colon carcinomas with 
different types of invasion. The number of cells displaying membranous or cytoplasmic 
Ccnd1 was significantly higher in peripheral cells than in inner cells in both collective 
and pushing invasion patterns of endometrial carcinoma, and in collective invasion 
pattern of colon carcinoma. Also, the cytoplasmic localization of Ccnd1 was higher 
when tumors infiltrated as single cells, budding or small clusters of cells. To evaluate 
cytoplasmic function of cyclin D1, we have built a variant (Ccnd1-CAAX) that remains 
attached to the cell membrane therefore sequestering this cyclin in the cytoplasm. 
Tumor cells harboring Ccnd1-CAAX showed high levels of invasiveness and metastatic 
potential compared to those containing the wild type allele of Ccnd1. However, Ccnd1-
CAAX expression did not alter proliferative rates of tumor cells. We hypothesize that 
the role of Ccnd1 in the cytoplasm is mainly associated with the invasive capability 
of tumor cells. Moreover, we propose that subcellular localization of Ccnd1 is an 
interesting guideline to measure cancer outcome.
INTRODUCTION
Cyclin D1 (Ccnd1) is among the 10 proto-oncogenes 
most frequently amplified in cancer [1]. Indeed, Ccnd1 was 
first characterized by studies of gene amplification as the 
gene affected by a chromosome inversion in parathyroid 
adenoma (PRAD1) and by a translocation t(11:14) in 
B-Cell Lymphomas (BCL-1) [2]. Alternatively, Ccnd1 
was also isolated from a human glioblastoma library in 
a yeast genetic selection using G1-cyclins depleted cells 
[3]. The importance of Ccnd1 as an oncogene has been 
extensively reported. For instance, overexpression of 
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Ccnd1 in the mammary gland is sufficient for the induction 
of mammary carcinoma [4]. This cyclin is a regulatory 
subunit of the cyclin-dependent kinases Cdk4/6 that are 
positive regulators of cell proliferation [5][6][7]. The 
Ccnd1·Cdk4 complex phosphorylates the transcriptional 
repressor pRB releasing the E2F-dependent transcription 
required for S phase entry [8]. Alternatively, Ccnd1 
regulates transcription of a different set of genes in a Cdk-
independent manner [9]. In both cases, the transcriptional 
changes induced by Ccnd1 accumulation in the nucleus 
trigger cell transformation [10]. 
Ccnd1 has been also associated with tumor 
invasion and metastasis in clinical studies. For instance, 
overexpression of Ccnd1 is connected with metastatic 
prostate cancer to bone [11]. Moreover, knock down 
of Ccnd1 in xenografted lung adenocarcinoma cells 
abrogates its metastatic potential [12]. Consistently, it 
is also established that Ccnd1 enhances cell migration 
and invasion as Ccnd1−/− cells show a reduction of their 
potential of invasiveness [13][14]. Interestingly, different 
works suggest that Ccnd1 is not restricted to the nucleus 
but is also associated to the cytoplasmic membrane, where 
it can activate cytoplasmic targets involved in cell invasive 
potential [15][16][17][18][19]. Cytosolic localization 
of Ccnd1 has been described in different tumors. For 
instance, an elevated expression of cytoplasmic Ccnd1 
has been detected by IHC in lymph node metastases 
originated from prostate cancer and is associated with poor 
survival [20]. However, the possible correlation between 
cytoplasmic Ccnd1 localization in neoplastic tissues and 
its ability to enhance invasion and metastasis has not 
been analyzed yet. In this work, we show that Ccnd1 
displays an asymmetric pattern of localization in different 
cancers, being more cytoplasmic and membranous in the 
peripheral and invasive regions of the neoplastic tissues. 
We have mimicked this feature in the cells by using a 
membrane-attached variant of Ccnd1. We have observed 
that the sequestration of Ccnd1 in the membrane enhances 
cell invasion and metastasis without affecting cell 
proliferation. In the same way as the nuclear localization 
of Ccnd1 is a signal of proliferation in the IHC analyses, 
we hypothesize that cytoplasmic localization could be a 
marker of invasiveness. 
RESULTS
Cytoplasmic-membranous Ccnd1 expression in 
human tumor tissue sections
To evaluate Ccnd1 localization, we performed 
IHC analysis of Ccnd1 on different tumoral types. First, 
we analyzed 55 samples of endometrioid endometrial 
carcinoma displaying different types of invasion 
(collective, pushing, glandular, MELF, single cell/small 
cell clusters, and blood vessel invasion; see Table 1). As 
we show in Figure 1A, the different types of invasion 
showed differential patterns of Ccnd1 localization. 
Cytoplasmic staining seems reticular and not diffuse, 
and staining in the plasma membrane of certain cells is 
also observed. According with previous works showing 
that Ccnd1 is localized in cell membranes [16], we 
have referred the non-nuclear Ccnd1 as cytoplasmic-
membranous localization. Ccnd1 cytoplasmic and 
membranous expression in collective and pushing 
patterns of endometrial samples was significantly higher 
in peripheral cells in comparison with the inner cells (P = 
< 0.00001 and P = 0.0004 respectively; Figure 1B). Single 
cell/small cell cluster, MELF and glandular patterns had 
the highest Ccnd1 cytoplasmic-membranous expression of 
all invasion types. 
In breast adenocarcinoma, cytoplasmic-membranous 
Ccnd1 protein expression was evaluated in 50 samples 
displaying different types of invasion (collective, 
glandular, indian-file). All invasion types showed high 
expression of cytoplasmic-membranous Ccnd1 but no 
differences between peripheral and inner cells in the 
collective invasion pattern (P = 0.18) (Figure 1C; see also 
Supplementary Figure 1A).
In prostatic adenocarcinoma, cytoplasmic-
membranous Ccnd1 protein expression was evaluated in 
50 samples, with different types of Gleason grade (3,4,5). 
Cytoplasmic-membranous Ccnd1 expression increased in 
parallel with the Gleason grade and, the higher expression 
occurred in pT3, that is, when tumor extends beyond 
the prostate (Figures 1D, trend test P = 0.003; see also 
Supplementary Figure 1C).
In colon adenocarcinoma, cytoplasmic-membranous 
Ccnd1 protein expression was evaluated in 50 samples, 
with different types of invasion (collective, pushing, 
budding, glandular). In the collective pattern, cytoplasmic-
membranous Ccnd1 expression was significantly higher in 
peripheral cells in comparison with inner cells (P = 0.01). 
In the pushing pattern, the difference between peripheral 
and inner cells was not statistically significant (P = 
0.15). The budding pattern had the highest cytoplasmic-
membranous Ccnd1 expression of all invasion types. 
Interestingly, the expression of Ccnd1 in the cytoplasm 
and membrane of glandular cells was very low (Figure 1E; 
see also Supplementary Figure 1B). 
Our results show that cytoplasmic-membranous 
staining for CcndD1 is weaker than nuclear, and a clear 
membrane signal is only observed in a small fraction 
of tissue cells. Probably, this result is not uncommon 
considering that the localization of Ccnd1 in the membrane 
of cultured cells was also detected only in a fraction of 
cells [16]. Three hours after seeding on fibronectin, mouse-
embryonic fibroblasts and tumor-endometrial cells showed 
Ccnd1 in the membrane of spreading cells (Supplementary 
Figure 2A). MFE cells reveal slightly membrane co-
localization of Ccnd1 with RalA (Supplementary Figure 
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2B). The presence of Ccnd1 only in the membrane of 
spreading cells agrees with the role of Ccnd1·Cdk4 in 
the regulation of Rho and Ral GTPases activity during 
adhesion and migration processes [14].
Since membranous-cytoplasmic accumulation of 
Ccnd1 was seen at the periphery of nests in collective 
and pushing invasion patterns of endometrial carcinoma 
samples, but also in correlation with Gleason grade, and 
pT3 in prostatic cancer, we selected endometrial and 
prostatic cancer as models to further validate the role of 
Ccnd1 in invasion.
The addition of a farnesylation motif to Ccnd1 
enhances its localization to the membranes
We have previously described that Ccnd1·Cdk4 
binds to Rgl2 that is a GEF of the Ral GTPases [18]. 
We hypothesized that Ccnd1·Cdk4 promotes Ral 
activation, and consequently cell invasion, through the 
regulation of Rgl2. For Ral activation, Rgl2 has to be 
recruited to the membrane by the GTPase Ras. An Rgl2 
variant containing the membrane-anchor motif of K-Ras 
promotes constitutive activation of Ral GTPase [21]. 
Then, to test whether the forced association of Ccnd1 
in the membrane could induce invasion of tumor cells, 
we have built a Ccnd1 with the same membrane-anchor 
motif of K-Ras fused at the C-terminus. This anchor motif 
contains a polybasic domain that drives the protein to the 
negatively charged membrane and a CAAX motif with a 
cysteine residue to attach a farnesyl tail [22] (Figure 2A). 
The endometrial cells were infected with lentiviruses 
containing either HA-Ccnd1 or HA-Ccnd1-CAAX alleles 
and were grown in complete medium. After five days, 
cells were fixed and processed for immunofluorescence 
using the rat 3F10 anti-HA antibody to visualize the 
localization of the exogenous Ccnd1. We observed that the 
wild type allele was localized in both the nucleus and the 
cytoplasm whereas the Ccnd1-CAAX allele was mostly 
localized at the membrane and cytoplasm (Figure 2B). 
Moreover, we determined that only Ccnd1-CAAX widely 
co-localizes in the membrane with the GTPase RalA that 
naturally contains a farnesylation motif and is localized in 
the membrane. These results indicate that the addition of 
K-Ras farnesylation motif to Ccnd1 can efficiently target 
it to the membrane. 
Table 1: Definition of the different types of invasion evaluated in the tumours
Invasive Type ECET1 BAC2 PAC3 CAC4
Collective invasion
Groups of cells invade the peritumoral stroma while maintaining cell-cell 
contacts.
x x x
Single-cells/single cluster of cells
In the absence of cell-cell adhesion, tumour cells invade as single cells or small 
cell clusters.
x
Budding
Presence of individual cells and small clusters of tumour cells at the invasive 
front of carcinomas.
x
MELF
The microcystic, elongated and fragmented (MELF) pattern include the presence 
of small dilated glands lined by cuboidal or flattened cells with eosinophylic 
cytoplasm.
x
Invasive glands
Invasive glands often have a slit-like appearance. x x x
Vascular invasion
When tumour cells are noted within or attached to the wall of the vascular space 
lined by flattened endothelial cells.
x
Pushing border invasion
Characterized by a cohesive tumour growth with well-delineated but infiltrating 
borders and “pushing” margins.
x x
Indian-file
The tumour cells spread between the collagen bundles in a single line. x
Gleason 3, 4, 5 x
pT3
Tumour extends beyond the prostate x
ECET1, Endometrial carcinoma of endometrioid type; BAC2, Breast adenocarcinoma; PAC3, Prostate adenocarcinoma, CAC4, 
Colorectal adenocarcinoma.
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Figure 1: Membranous-cytoplasmic Ccnd1 expression at the invasive front is higher in peripheral cells, in large 
invasive cell clusters or in specific types of invasion. A. Representative images showing Ccnd1 expression in endometrioid 
carcinomas of the endometrium (100µm bar). Different types of invasion are considered (collective, pushing, MELF, glandular, single 
cells/small cluster of cells, and vascular). Arrows indicate Ccnd1 stain in the membrane. Evaluation of the differences in membranous-
cytoplasmic Ccnd1 expression among the different types of invasion in endometrioid endometrial carcinomas B., ductal breast carcinoma 
C., prostatic carcinoma according to Gleason grade or invasion beyond the prostate (pT3) D. and colonic carcinoma E. Bars represent 
mean percentages of positivity and segments one standard deviation. Significant differences between selected pairs are shown with their 
corresponding p-value, as computed with the linear mixed models. For prostate, p-value to evaluate the increasing trend is shown. 
Oncotarget26983www.impactjournals.com/oncotarget
To confirm this result, we analyzed subcellular 
localization of Ccnd1 and Ccnd1-CAAX alleles by 
cell fractionation. Endometrial cells (Ishikawa) were 
infected with virus containing Ccnd1 or Ccnd1-CAAX 
and processed for cell fractionation using a Subcellular 
Protein Fractionation kit (Thermo Scientific-Pierce; 
78840). We obtained a soluble fraction containing 
cytosolic and nuclear soluble proteins and a membrane 
fraction as indicated by the reference proteins (Figure 
2C). We observed that the presence of Ccnd1-CAAX was 
extensively enriched in the membrane fraction (Figure 
2C). Interestingly, the endogenous and exogenous wild 
type Ccnd1 exhibited also a reduced portion of the protein 
in the membrane fraction in accordance with previous 
Figure 2: Ccnd1-CAAX is localized in cell membranes of tumor cells. A. Schematic representation of C-terminal fusion 
of the anchor domain of human K-Ras with Ccnd1 protein. B. MFE cells infected with HA-Ccnd1 or HA-Ccnd1-CAAX or an empty 
vector were fixed in 4% paraformaldehyde and permeabilized with 0.2% triton-100X. Images were acquired by confocal microscopy 
(10µm bar). Nuclei were stained with Hoescht (blue). The antibodies used were anti-HA (rat monoclonal 3F10, green) and anti-RalA 
(mouse monoclonal, red). C. Ishikawa cells infected with HA-Ccnd1 or HA-Ccnd1-CAAX were submitted to subcellular fractionation (see 
“Materials and Methods”). Fractions were analyzed by immunoblotting to detect Ccnd1 in soluble and membrane fractions. Quantification 
of Ccnd1 levels are shown at the bottom of the panel. Tubulin as a cytosol marker, Transferrin Receptor as a membrane marker and PCNA 
as a nucleoplasm marker were used to control fractionation. D. Cdk4 distribution in soluble and membrane fractions from the experiment 
in C. Quantification of Cdk4 levels are shown at the bottom of the panel. 
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works suggesting that Ccnd1 interacts with membrane-
associated proteins as filaminA or RalA [16][18]. In these 
works, it has been suggested that cytoplasmic functions 
of Ccnd1 are Cdk4-dependent. For that reason, we have 
tested whether Cdk4 was also present in the membrane 
fraction (Figure 2D). As expected, a portion of Cdk4 was 
in the membrane and it was also enriched after Ccnd1-
CAAX expression. All these results indicate that the 
expression of Ccnd1-CAAX promotes the accumulation 
of Ccnd1-Cdk4 complexes in the membrane. 
The sequestration of Ccnd1 in the membrane 
increases the invasiveness of tumor cells but does 
not change proliferation in those cells
Our study of Ccnd1 localization in cancer tissues 
suggested that the cytoplasmic localization of Ccnd1 may 
be related to the invasiveness of tumor cells (see above). It 
has also been reported that Ccnd1 could have cytoplasmic 
substrates involved in the regulation of cell migration 
and invasion [16][18]. For these reasons, we sought to 
Figure 3: The membrane-associated Ccnd1 enhances invasiveness of tumor cells. A. R3327-5’A rat cells were infected 
with interference shRNA against rat Ccnd1 (shD1, Sigma). Cells expressing the shRNA were further infected with human Ccnd1, Ccnd1-
CAAX, Ccnd1
K112E
-CAAX or with an empty lentiviral vector. For invasion assays, 5x104 co-infected cells were seeded in 24-well transwell 
filters previously coated with matrigel, and allowed to invade for 24 hours. After this time all cells were fixed and stained with Hoescht 
-input-. Then, the remaining cells at the bottom of the filter were washed and Matrigel-embedded cells were counted -matrigel- . B. Relative 
values from the experiment in A are expressed in mean ± sem. Data are from at least three independent experiments. Significance values 
were determined by one way ANOVA and Holm Τ-statistic post-test (**p < 0.01). C. Immunoblot showing the expression of HA-Ccnd1 in 
the co-infected cells. Actin was used as a loading control.
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analyze whether the membrane-associated allele of Ccnd1 
could significantly increase the invasiveness. We infected 
R3327-5’A rat tumor cells that had endogenous Ccnd1 
downregulated by RNA interference with lentiviruses 
containing human HA-Ccnd1, HA-Ccnd1-CAAX or 
HA-Ccnd1
K112E
-CAAX or empty vector. After five days 
growing in complete medium, those cells were processed 
to reveal “in vitro” their invasive potential. We observed 
that the expression of Ccnd1-CAAX significantly induced 
the invasiveness of the R3327-5’A cells in comparison 
with the expression of the wild type allele or the empty 
vector (Figure 3A and 3B). It has been previously reported 
that Ccnd1 enhanced cell invasiveness by a Cdk4-
dependent mechanism [14]. In accordance with that result, 
we also remarked that the expression of the inactive allele 
Ccnd1
K112E
-CAAX was unable to promote cell invasion. 
All these results suggest that the sequestration of an active 
complex Ccnd1-Cdk4 in the membrane increases the 
invasiveness of tumor cells. 
It has been reported that overexpression of Ccnd1 
reduces doubling-cell time and increases clonogenic 
and anchorage-independent growth in transformed 
cells [23][24]. Moreover, Ccnd1 alleles or mutants that 
enhance nuclear accumulation increase clonogenic 
growth capability over the wild type allele, even in non-
transformed cells [25][26]. Then, we questioned whether 
the membrane-associated allele of Ccnd1 could estimulate 
cell proliferation. To test this hypothesis, MFE cells were 
infected with lentiviruses containing HA-Ccnd1 or HA-
Ccnd1-CAAX or empty vector. After growing, those 
cells were handled to determine the proliferation rate 
and clonogenic and anchorage-independent growth. The 
expression of Ccnd1-CAAX did not significantly change 
the proliferation rate of MFE cells compared to the wild 
type Ccnd1 (Supplementary Figure 3A). Also we noted 
that neither the clonogenic nor non-adherent growth was 
Figure 4: The membrane-associated Ccnd1 promotes Ral-GTPase activation. A. HEK293T cells were co-transfected with 
HA-RalB and either HA-Ccnd1, or HA-Ccnd1-CAAX or an empty vector as a negative control. Twenty-four hours after transfection, active 
RalB-GTP was affinity purified with RalBP-beads from cell lysates and detected by immunoblotting with anti-HA antibody. HA-D1, HA-
RalB and HA-RalB-GTP amount from a representative experiment is shown. RalBP-beads and actin were used as loading controls. B. The 
experiment was independently repeated four times. Relative mean values ± sem for the HA-RalB-GTP/ total HA-RalB ratio are plotted. 
Significance values were determined by one way ANOVA and Holm Τ-statistic post-test (*p < 0.05; **p < 0.01). C. R3327-5’A rat cells 
were infected with interference shRNA against RalB (shRalB) or with scramble (scr) as a control. Relative invasion values are expressed in 
mean ± sem. Data are from three independent experiments. Significance values were determined by one way ANOVA and Holm Τ-statistic 
post-test (**p < 0.01). D. Immunoblot showing the levels of expression of RalB in (C). Gel stain was used as a loading control.
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modfified by the expression of Ccnd1-CAAX in MFE cells 
(Supplementary Figure 3B and 3C). These results suggest 
that sequestration of Ccnd1 in the membrane does not 
modify any form of growth in tumor cells.
The attachment of Ccnd1 in the membrane 
promotes RalGTPase activation
In a previous report we described that cyclin 
D1 enhanced cell motility through the activation of 
RalGTPases [18]. Then, we expected that the attachment 
of Ccnd1 to the membranes would ameliorate the 
activation of RalGTPases and consequently the efficiency 
of cell invasion. To analyze this possibility, we have co-
expressed HA-Ccnd1 or HA-Ccnd1-CAAX with HA-RalB 
in HEK293T cells and then, we determined the levels 
of the HA-RalB loaded with GTP in those cells. The 
expression of Ccnd1-CAAX enhanced RalB activity better 
than the expression of Ccnd1, even though the increment 
in RalB activity was not statistically significant (Figure 
4A and 4B). Since the membrane attachment of Ccnd1 
was able to appreciably improve the invasiveness of tumor 
cells, we tested whether the improvement in invasion was 
RalB-dependent. The down-regulation of RalB by shRNA 
in R3327-5’A cells expressing Ccnd1-CAAX partially 
reduced the invasion capacity of these cells (Figure 4C and 
4D). Our data suggest that membrane-associated Ccnd1 
promotes invasion in some extent through Ral activation, 
but it may have other interactors or substrates than Ral 
GTPases to completely explain the role of Ccnd1 in the 
membrane. 
The presence of Ccnd1 attached to the membrane 
of tumor cells stimulates the tumor invasion and 
metastasis
Ccnd1 has been described as an inductor of 
metastasis in mice and in clinical studies [27][12][11]. 
Figure 5: The membrane-associated Ccnd1 enhances lung metastatic activity of endometrial tumor cells. A. MFE cells 
stably expressing luciferase were used for metastasis assay. Cells harboring Ccnd1 or Ccnd1-CAAX were injected in SCID-hairless mice. 
Four weeks after injection, animals expressing Ccnd1-CAAX showed lung metastasis. Representative images of the body luminescence 
(top) and lungs luminiscence (bottom) are shown. B. The number of lung nodules from eight animals in A was inferred from luminescence 
and represented. Significance values were determined by a Mann-Whitney test. C. Representative HA-immunohistochemistry images of 
lung nodules are shown. D. MFE cells expressed similar amounts of Ccnd1 or Ccnd1-CAAX. A protein extract was obtained from the cells 
before injection to the mice, and the amount of Ccnd1 was analyzed by immunoblot. Actin was used as a loading control.
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To measure the relevance of the membrane-attachment 
of Ccnd1 in the induction of metastasis “in vivo”, we 
injected MFE cells expressing Ccnd1-CAAX or Ccnd1 
directly to the bloodstream of 8-weeks-old nude mice. 
Animals were sacrificed four weeks after injection, their 
lungs examined for metastatic growth and the presence 
of nodules in the lungs was calculated (Figure 5A and 
5B). We observed that the expression of Ccnd1-CAAX 
significantly stimulated MFE-dependent metastasis (six 
out of the eight animals exhibited apparent nodules). After 
four weeks, only one animal manifested metastasis when 
the wild type allele of Ccnd1 was expressed in MFE cells. 
We confirmed the presence of the MFE cells in the nodules 
by revealing HA signal in the tissues, HA-Ccnd1-CAAX 
was detected in the membrane of cells (Figure 5C). Note 
that the abundance of metastases in the samples expressing 
Ccnd1-CAAX versus Ccnd1 was not due to differences 
in the expression levels (Figure 5D). Similar results were 
obtained using prostatic cancer cells (Supplementary 
Figure 4). Overall, this result suggests that the presence 
of Ccnd1 in the cell membrane of tumor cells may be a 
marker of poor prognosis. This hypothesis is consistent 
with the data about cancer tissues analyzed in the first part 
of this paper.
DISCUSSION
The molecular mechanisms involved in both 
individual and collective tumor cell invasion are not fully 
understood. From the histopathological viewpoint, there 
are many different patterns of invasion, which frequently 
coexist in different areas of the same tumor. Some 
tumor types show specific patterns of invasion, which 
are not seen in other types of cancer. This phenomenon 
is clearly represented by endometrial cancer, which has 
a peculiar type of invasion (MELF, characterized by 
microcystic, elongated, and fragmented tumor cells in 
a fibromyxoid stroma) that is very infrequent in other 
tumor types. A relevant question is whether there are 
generic elements altered in all those patterns of invasion 
[28][29]. In this study, we have found an increase of the 
membranous-cytoplasmic Ccnd1 expression in cells from 
specific invasion patterns (single cell/small cell clusters, 
buds, glandular) in which tumor cells are in contact 
with the adjacent stroma. More interestingly, increased 
membranous-cytoplasmic Ccnd1 expression was seen in 
peripheral cells in comparison with inner cells, whenever 
cancer cells infiltrate the stroma as large cell masses 
(collective or pushing patterns). Moreover, membranous-
cytoplasmic Ccnd1 expression was seen in peculiar forms 
of invasion, such as the MELF pattern. Considering 
all these data, we hypothesize that the presence of 
membranous-cytoplasmic Ccnd1 is a generic indicator of 
invasive phenotype. 
We have also shown that forced attachment of 
Ccnd1 to the membrane (caused by Ccdn1-CAAX 
expression) induces tumor cell invasiveness and 
metastasis in tumor cells through a RalB-dependent 
mechanism. Considering all the data cited, we propose 
that the localization of Ccnd1 in the cytoplasm do not 
merely mean an appeasement of proliferation but could 
be a device to induce migration and invasion. Certainly, 
the role of Ccnd1 in the regulation of cell migration 
and invasion is also dependent on nuclear functions. Li 
et al, 2006 showed that the transcriptional repression of 
the cytoskeleton regulators ROCK II and TSP-1 exerted 
by Ccnd1 is required for efficient fibroblasts migration. 
Then, our proposal should not be categorically understood 
like that Ccnd1 shows a dichotomy as an oncogene, 
proliferation versus invasion, that can be unveiled 
depending on the subcellular localization, nucleus versus 
cytoplasm, respectively. By immunohistochemistry, Ccnd1 
shows a diverse pattern of localizations in cancer tissues 
and cytoplasmic accumulation does not mean nuclear 
exclusion and vice versa ([30]; our results). Thus, we can 
envisage that when a detectable amount of Ccnd1 moves 
to the cytoplasm may be suggestive of an increment in the 
invasive potential of the cells. 
The knowledge of the subcellular pattern of Ccnd1 
may be interesting to determine the proliferative and 
invasive ability of specific tumors. It is well accepted that 
Ccnd1 nuclear accumulation is indicative that the tumor 
has a significant mitotic activity. For instance, cytoplasmic 
localization of Ccnd1 is observed in low-grade prostate 
carcinomas with reduced Ki-67 positivity whereas nuclear 
Ccnd1 is associated with high degree and elevated Ki-67 
[30]. Conversely, cytoplasmic expression of Ccnd1 has not 
been taken into account as an indicator of tumor status 
other than the non-proliferative state. Nevertheless, single 
cell and MELF pattern in endometrial carcinoma, budding 
in colon cancer and pT3 tumors of prostatic carcinomas 
each of them exhibiting membranous-cytoplasmic Ccnd1 
expression, have been associated with aggressiveness 
[31][32][33][34][35][36][37]. Then, we propose that 
cytoplasmic Ccnd1 could be indicative of tumor cells with 
a high invasive potential.
MATERIALS AND METHODS
Tumor tissue samples
Tumor samples, classified following the most 
recent WHO criteria, included 55 cases of endometrioid 
endometrial carcinoma, 50 cases of colorectal 
adenocarcinoma, 50 cases of breast carcinoma, and 50 
cases of prostatic carcinoma. They were obtained from the 
Surgical Pathology files of Hospital Universitari Arnau de 
Vilanova, and IRBLLEIDA Biobank in Lleida, Spain. A 
specific informed consent was obtained from each patient 
in accordance with the protocols approved by the Local 
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Ethical Committee. Tumors had been fixed in formalin 
and embedded in paraffin. Selected sections and paraffin 
blocks containing the invasive front of the tumors into the 
adjacent tissue were retrieved. Several specific types of 
tumor invasion, depending of tumor site, were evaluated 
(Table 1). In prostatic cancer, Gleason grade (3, 4 and 
5) was taken as indirect indicator of invasion, and pT3 
prostatic cancers were selected as the subgroup exhibiting 
the most prominent invasive features, by infiltrating peri-
prostatic tissues.
Cell culture
MFE and Ishikawa (IK) cells are from endometrial 
adenocarcinoma. R3327-5’ rat prostate-tumor cells were 
kindly provided by M. Hendrix. HEK293T cells were 
obtained from the American Type Culture Collection. 
Cells were maintained at 37ºC in a 5% CO
2 
incubator, and 
grown in Dulbecco’s modified Eagle’s medium (DMEM) 
supplemented with 10% Fetal Bovine Serum (FBS), 
100 µg/ml penicillin/streptomycin and 2 mM glutamine. 
Transient transfection of vectors was performed 
with Lipofectamine 2000 (Invitrogen) according to 
manufacturer’s instructions. For lentivirus production, 
HEK293T cells were transfected with lentiviral expression 
vectors, envelope plasmid pVSV.G, and packaging 
plasmid pHR’82∆R at a 2:1:1 ratio. 
Expression vectors
Human CCND1 wild type and CCND1
K112E
 inactive 
allele were used to obtain an N-terminal 3xHA fusion 
under the UBI promoter in a lentiviral vector derived 
from pDSL (Invitrogen) or under the CMV promoter in 
a pCDNA3 vector. In these constructs the 3’ end of the 
K-Ras ORF containing the CAAX motif (GGC TGT 
GTG AAA ATT AAA AAA TGC ATT ATA ATG TAA) 
was fused to the 3’ end of the CCND1 ORF. For RalB 
activity assay we performed an N-terminal 3xHA fusion 
to human RalB (image 3880116) and cloned in a pCDNA3 
vector. Details of all constructs are available upon request. 
The RALB MISSION shRNA TRCN0000072957 and 
the CCND1 MISSION shRNA TRCN0000026883, both 
cloned in a pLKO.1-puro, were obtained from Sigma. 
Immunofluorescence
Briefly, cells were quickly washed in PBS and fixed 
in 4% paraformaldehyde for 15 min at room temperature. 
Fixed MFE cells or fibroblasts were permeabilized with 
0.2% triton-100X for 3 min at room temperature, and 
blocked with 3% BSA. Primary antibodies were combined 
with adequate Alexa488 and/or Alexa594-labeled 
secondary antibodies (Molecular Probes) in PBS with 
0.3% BSA. Nuclei were stained with Hoechst (Sigma). 
Images were acquired using 60X objective in an Olympus 
FV1000 confocal system. The antibodies used were anti-
HA (rat monoclonal 3F10, green), anti-Ccnd1 (rabbit 
monoclonal EP12 Dako, green) and anti-RalA (mouse 
monoclonal, red).
Protein fractionation and immunoblot
Protein fractionation was performed with the 
Subcellular Protein Fractionation kit for cultured cells 
(Thermo Scientific-Pierce; 78840). Soluble fraction 
corresponds to a mixture of cytosolic and nuclear soluble 
fractions described in the supplier’s instructions.
For immunoblot, protein samples were resolved 
by SDS-PAGE, transferred to PVDF membranes 
(Millipore), and incubated with primary antibodies anti-
Ccnd1 (monoclonal DCS-6, BD Pharmigen), anti-Cdk4 
(polyclonal C-22, sc-260), anti-HA (rat monoclonal 3F10, 
Roche), anti-TfR (monoclonal H68.4, Invitrogen), anti-
RalB (rabbit polyclonal, Cell Signaling), anti-PCNA 
(monoclonal PC10, Abcam) and anti-tubulin (monoclonal 
B-5-1-2 Sigma). Appropriate peroxidase-linked secondary 
antibodies (GE Healthcare UK Ltd) were detected using 
the chemiluminescent HRP substrate Immobilon Western 
(Millipore). Chemiluminescence was recorded with a 
ChemiDoc-MP imaging system (BioRad). 
Cell invasion assay
We performed cell invasion assays in 6.5-mm filters 
of 8.0 pore size (Transwell, Corning). Filters were coated 
with Matrigel (reduced-factors, BD Biosciences) in the 
upper side. Then, cells (5x104) were seeded in the bottom 
side of the filter for four hours to allow their attachment. 
Afterwards, filters were loaded with DMEM 10% serum 
and incubated in 24-well plates containing serum-free 
medium for 24 hours. Under these conditions, some cells 
migrate from the bottom to the upper side of the filter 
invading the Matrigel. All cells were fixed and stained 
with Hoescht. Remaining cells at the bottom of the filter 
were removed and Matrigel-embedded cells were counted.
Ral pull-down assay
The Ral activation was analyzed by measuring the 
GTP-bound form of Ral. The assays were performed by 
using RalBP1 agarose (Upstate, cat# 14-415) according 
to the manufacturer’s instructions. Cell lysates were 
obtained from one 100 mm plate from transfected 
HEK293T cells. The lysis buffer used was 50 mM Tris 
pH 7.5, 200 mM NaCl, 2.5 mM MgCl
2
, 2.5 mM DTT, 
1% Triton and protease and phosphatase inhibitors. 0.6 ml 
of cell lysate was incubated with 10µg of RalBP1 beads 
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during 30 min at 4ºC and, after several washes, agarose 
beads were resuspended in 2x Laemmli buffer. Samples 
were separated by SDS-PAGE, transferred to PVDF 
membranes, and immunoblotted.
Metastasis assay
The procedure performed in this study followed 
the National Institutes of Health Guidelines for the Care 
and Use of Laboratory Animals, and was compliant with 
the guidelines of our Institution (UdL). Immunodeficient 
female SCID hr/hr mice (8-week-old) were maintained 
in Specific Pathogen Free (SPF) conditions, and 
were inoculated with 5x105 MFE cells by retroorbital 
intravenous injection. Animals were sacrificed four weeks 
afterwards. For the metastasis assays injecting R3327-5’A 
cells, we have used fewer cells (2.5x104) and analyzed 
the lungs one week after injection, as those cells are very 
aggressive inducing metastasis. 
Immunohistochemistry
Paraffin blocks of human tumor tissue samples were 
sectioned at a thickness of 3μm, dried for 1 hour at 65°C 
before deparaffinization, rehydration, and epitope retrieval 
in the Pre- Treatment Module, PT LINK (Dako, Glostrup, 
Denmark) at 95°C for 20 minutes in 50Å~ Tris/EDTA 
buffer, pH 9. Before staining the sections, endogenous 
peroxidase was blocked. Samples were subjected to IHC 
for Ccnd1 (1:25, EP12, DAKO), visualized with the 
EnVision FLEX Detection Kit (Dako, Glostrup, Denmark) 
using diaminobenzidine chromogen as a substrate. Slides 
were counterstained with hematoxylin. Negative controls 
were obtained without the addition of the primary 
antibody. The immunohistochemical analysis was 
conducted by pathologist and a researcher to ensure a pre-
established histological criteria. IHC staining was assessed 
using ImageJ formal manual count method, 1,47v by 
Wayne Rasband (National Institutes of Health, USA), by 
analyzing tumor cells in a mean number of 5 invasive foci 
per case. Results indicate proportion of cells positively 
stained in the cytoplasm and membrane of selected fields 
(approximately 50 high resolution fields, X40). In the 
collective and pushing patterns, we assessed the difference 
in positively stained cytoplasm and membrane between 
peripheral and inner cells. Table 1 presents all invasion 
types evaluated in each of the different tumours studied.
Regarding mouse tissues, lung tissue samples were 
fixed with PFA. Blocks were sectioned at a thickness of 
3 μm and dried for 1 h at 65 °C, before being dewaxed 
in xylene and rehydrated through a graded ethanol series, 
then washed with PBS. Antigen retrieval was performed 
by heat treatment in a pressure cooker for 2 min in EDTA 
(pH 8.9). Before staining the sections, endogenous 
peroxidase was blocked. The antibody used was anti-HA 
12CA5 mouse monoclonal (ascitic fluid). After incubation, 
the reaction was visualized with the EnVision Detection 
Kit (Dako), using diaminobenzidine chromogen as a 
substrate. Sections were counterstained with hematoxylin. 
Statistical analysis
For IHC data, mean and standard deviation 
were computed to assess the positivity observed in the 
cytoplasm for each tumoral type (endometrium, breast, 
prostate and colon) when comparing different invasion 
types or histological grades. Linear mixed models were 
used to evaluate the significance of the differences, 
using a random effect to take into account the samples 
corresponding to the same individual. All analyses were 
made using R, setting the threshold for significance at 5% 
(alfa = 0.05).
For cell data, comparisons among groups were made 
by one way ANOVA and Holm Τ-statistic post-test (*p < 
0.05, **p < 0.01, ns no significant).
For animal studies we have used the Ene 3.0: 
Program to calculate sample size. This software was 
developed by the Department of Applied Statistics of 
Autonomous University of Barcelona and is distributed by 
GlaxoSmithKline. No specific method of randomization 
was used but the group allocation was done randomly. 
Significance values were determined by Mann-Whitney 
U-Test Calculator (significance values 0.05 and two-tailed 
test).
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